Company news

Caribou Biosciences, Inc. news in 2023

Caribou Biosciences, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

December 11, 2023

Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

November 6, 2023

Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

November 5, 2023

Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

October 17, 2023

Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer

September 26, 2023

Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

August 7, 2023

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

July 12, 2023

Caribou Biosciences Announces Proposed Public Offering of Common Stock

July 12, 2023

Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering

July 12, 2023

Caribou Biosciences Announces $25 Million Equity Investment from Pfizer

July 5, 2023

Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

May 8, 2023

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

May 7, 2023

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting

April 16, 2023

Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

April 3, 2023

Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients

March 28, 2023

Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

March 28, 2023

Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 8, 2023

Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

March 7, 2023

Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Decks in 2023